Loading
A phase 3 trial of TQB2930 and Trastuzumab in HER2-positive breast cancer, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer is a phase 3 interventional study registered as NCT07047365 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 416 participants planned, started 2025-07-25 and due to reach its primary completion in 2028-06. Interventions recorded: TQB2930+ chemotherapy and Trastuzumab+ chemotherapy.
Shares TQB2930, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares TQB2930, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Trastuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Trastuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Trastuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Trastuzumab, Monoclonal antibodies and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer and the tag pipeline.